Guggenheim on Cabaletta Bio (CABA): 'compelling evidence that CAR-T activity can be achieved without preconditioning'
Guggenheim analyst Yatin Suneja reiterated a Buy rating and $16.00 price target on Cabaletta Bio Inc. (NASDAQ: CABA).The analyst comments ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)